SARS-CoV-2 (COVID-19) Spike 681P Antibody [8G10C8]

blue ice or RT

Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (25%)

WB: 1 μ g/mL.

Antibody validated: Western Blot in human samples. Anti-SARS-CoV-2 Spike 681P antibody can detect SARS-CoV-2 WT Spike S1 protein, but not SARS-CoV-2 Alpha Variant (B.1.1.7, UK) S1 protein by ELISA and WB. It can also detect WT peptide (681P), but not mutant peptide (681H). All other applications and species not yet tested.

Monoclonal

IgG3

Anti-SARS-CoV-2 Spike 681P antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 Spike 681P antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

S

1791269090

Optimal dilutions for each application to be determined by the researcher.

surface glycoprotein

In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7 and named as Alpha variant, was discovered in the United Kingdom. This lineage developed 14 lineage-specific amino acid replacements and 3 deletions. These changes caused an increase in transmission of Alpha variant (B.1.1.7 lineage) by at least 50%, leading to increased disease severity and higher death rates. The effectiveness of COVID19 vaccines are not affected by the Alpha variant. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H mutation in the cleavage site of spike protein. This location is one of the residues that make up the furin proteolytic cleavage site between S1 and S2 in spike protein.

Gu et al. Science 369(6511):1603-1607

Davies et al. Science 372(6538):eabg3055.

Graham, et al. The Lancet Public Health. 6(5): e335-e345.

Figure 1 ELISA Validation of Spike 681P Antibodies with SARS-CoV-2 Spike S1 Protein
Coating Antigens: SARS-CoV-2 spike S1 proteins: WT and alpha variant (B.1.1.7, UK), 2 μ g/mL, incubated at 4 ˚ C overnight.Detection Antibodies: SARS-CoV-2 Spike 681P antibody, PM-9367, dilution: 1-3000 ng/mL, incubated at RT for 1 hr.Secondary Antibodies: Goat anti-mouse HRP at 1:5, 000, incubated at RT for 1 hr.SARS-CoV-2 spike 681P antibody (PM-9367) detected WT spike S1 protein (10-300), but not alpha variant spike S1 protein by ELISA.

Figure 3 ELISA Validation of Spike 681P Antibodies with Mutant and WT Peptide
Coating Antigen: SARS-CoV-2 spike S1 peptides: WT (9091P) and alpha variant (B.1.1.7, UK) (9359P), 1 μ g/mL, incubate at 4 ˚ C overnight.Detection Antibodies: SARS-CoV-2 681P antibody, PM-9367, dilution: 0.3-1000 ng/mL, incubated at RT for 1 hr.Secondary Antibodies: Goat anti-mouse HRP at 1:5, 000, incubated at RT for 1 hr.SARS-CoV-2 spike 681P antibody (PM-9367) detected WT peptide (681P, 9091P), but not alpha variant spike S1 peptide (681H, 9359P).